Why the study?
Does candesartan improve diastolic dysfunction and alter myocardial collagen turnover in type 2 diabetic patients?
Does candesartan improve diastolic dysfunction and alter myocardial collagen turnover in type 2 diabetic patients?
Chronic ARB therapy with candesartan improves diastolic dysfunction and attenuates myocardial fibrosis in type 2 diabetic patients by facilitating collagen degradation.
Answers are grounded in this paper and cite their sources.
Candesartan was associated with E/A improvement in T2DM; leaves open whether ARBs causally alter collagen turnover or diastolic function.
BACKGROUND: We attempted to test the hypothesis that chronic angiotensin II type 1A receptor blockade (ARB) alters myocardial collagen turnover leading to an improvement of diastolic dysfunction in diabetic patients. METHODS AND RESULTS: Forty-eight type 2 diabetic patients were divided into 2 groups: 38 treated with candesartan for 6 months, and 10 without candesartan, as controls. Doppler mitral flow velocity pattern and biomarkers of collagen type I turnover were assessed before and after ARB during a 6-month period. The mitral E/A ratio increased from 0.65+/-0.11 to 0.75+/-0.19. The carboxy-terminal propeptide of procollagen type I (PIP), an index of collagen type I synthesis, decreased and the carboxy-terminal telopeptide of collagen type I (CITP), an index of collagen type I degradation, increased following ARB. Consequently, the PIP/CITP ratio, an index of coupling between the synthesis and degradation of collagen type I, decreased. None of the indexes changed in the control group. The change in left ventricular chamber stiffness did not correlate with the change in PICP (r=0.08, p=NS), but it did with the changes in CITP or in the PIP/CITP ratio (r=0.35, p<0.05; r=0.39, p<0.05). CONCLUSIONS: Chronic ARB improves diastolic dysfunction in diabetic patients, at least partially through the attenuation of myocardial fibrosis, by regulating collagen turnover, particularly by facilitating collagen degradation.
No takes yet. Share an insight, caveat, or question.
Kawasaki et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: